Survey to describe impact of reflux disease on everyday life in GERD patients before and after 4 weeks treatment.
Study identifier:NIS-GVN-DUM-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Epidemiological survey to describe impact of reflux disease on everyday life in GERD patients before and after 4 weeks treatment
Medical condition
Gastroesophageal Reflux Disease
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
2091
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Oct 2008
Primary Completion Date: -
Study Completion Date: 01 Jun 2009
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy | - |
Contacts
Investigators
Principal Investigator
Ta Long
Vietnam Association of Gastroenterology
